Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer

Cancer

Volumn 120, Issue 10, 2014, Pages 1586-1593

  Dev, Rony ^a   Hui, David ^a   Del Fabbro, Egidio ^b   Delgado Guay, Marvin O ^a   Sobti, Nikhil ^a   Dalal, Shalini ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

advanced cancer; hypogonadism; palliative care; survival; symptom management

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIFEDIOL; CYANOCOBALAMIN; HEMOGLOBIN; HYDROCORTISONE; OPIATE; TESTOSTERONE; THYROTROPIN;

ADULT; ADVANCED CANCER; AGED; ANXIETY; ARTICLE; CACHEXIA; CANCER SURVIVAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DROWSINESS; DRUG USE; DYSPNEA; FATIGUE; HUMAN; HYPOGONADISM; INFLAMMATION; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEEP DISORDER; SUBSTANCE USE; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; VERY ELDERLY; WEIGHT REDUCTION; WELLBEING;

ADVANCED CANCER; HYPOGONADISM; PALLIATIVE CARE; SURVIVAL; SYMPTOM MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANDROGENS; ANOREXIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CACHEXIA; COST OF ILLNESS; HEMOGLOBINS; HUMANS; HYDROCORTISONE; HYPOGONADISM; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TESTOSTERONE; TEXAS; THYROTROPIN; VITAMIN B 12; VITAMIN D; WEIGHT LOSS;

EID: 84899988371     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28619     Document Type: Article

References (25)

1. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006; 107: 2949-2957.
2. Burney BO, Hayes TG, Smiechowska J, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 2012; 97: E700-E709.
3. hlebowski RT, Heber D,. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982; 42: 2495-2498.
4. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W,. The impact of chemotherapy on Ledydig cell function in long term survivors of germ cell tumors. Cancer. 2001; 91: 1297-1303.
5. Dev R, Del Fabbro E, Bruera E,. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer. 2007; 110: 1173-1177.
6. Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006; 106: 2583-2591.
7. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E,. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100: 851-858.
8. Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010; 39: 1016-1024.
9. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K,. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991; 7: 6-9.
10. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS,. Measurement of total testosterone in adult men: comparison of current laboratory methods versus liquid chromatograph-tandem mass spectrometry. J Clin Endocrinol Metab. 2004; 89: 534-543.
11. Vermeulen A, Stoica T, Verdonck L,. The apparent free testosterone concentration, an index of androgenicity. J Clin Endocrinol Metab. 1971; 33: 759-767.
12. Bammann BL, Coulam C, Jiang NS,. Total and free testosterone during pregnancy. Am J Obstet Gynecol. 1980; 137: 293-298.
13. Gönen M,. Analyzing Receiver Operating Characteristics Curves with SAS. Cary, NC: SAS Institute Inc.
14. Wheeler MJ,. The determination of bio-available testosterone. Ann Clin Biochem. 1995; 32 (pt 4): 345-357.
15. Vermeulen A,. Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab. 2001; 86: 2380-2390.
16. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR,; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724-731.
17. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C,. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60: 762-769.
18. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ,; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002; 8: 440-456.
19. Dev R, Del Fabbro E, Schwartz GG, et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist. 2011; 16: 1637-1641.
20. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH,. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013; 169: 725-733.
21. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011; 165: 687-701.
22. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009; 94: 2482-2488.
23. Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013; 21: 2599-2607.
24. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH,. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007; 156: 595-602.
25. Bremmer WJ, Vitiello MV, Prinz PN,. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983; 56: 1278-1281.